Education:

Louisiana State University Shreveport: Human Development, B.S.

Bossier Parish Community College: General Studies, A.A.

About:

Mrs. Adkison is a Clinical Research Associate II of Proxima Clinical Research a partner for the emerging biotech and medical device industry. Mrs. Adkison has served in a number of clinical research roles. Previously, as a Clinical Research Associate with PPD, she gained extensive experience in overseeing all aspects of study site monitoring including routine monitoring and close-out of clinical sites, maintenance of study files, conduct of pre-study and initiation visits. As a Project Manager with Mary Crowley, she has proven excellence in administering all clinical aspects of clinical studies and recommending changes in implementation of various plans, designing all project metrics and timeframe for project completion. She has been involved in numerous clinical trials for both investigator-initiated trials and pharmaceutical companies.  

Mrs. Adkison graduated from Louisiana State University with a Bachelor of Science in Human Development. She has been involved in numerous clinical trials for both investigator-initiated trials and pharmaceutical companies.

Positions and Honors:

Proxima Clinical Research, Inc., Houston, Texas
Clinical Research Associate II

IQVIA
Site Manager

Neurology Consultants of Dallas, P.A., Dallas, TX  
Clinical Research Coordinator

Pharmaceutical Product Development, LLC., Austin, Texas
Senior Clinical Research Associate

ICON Clinical Research, Sugarland, TX
Clinical Research Associate

Mary Crowley Cancer Research Centers, Dallas, TX
Project Manager

J. Gary Booker, MD., Shreveport, LA
Clinical Research Coordinator

Contributions to Science:

Ms. Adkison has contributed to the following peer-reviewed publications:  

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of LY3819253 in Preventing SARS-CoV-2 infection and COVID-19 in Skilled Nursing and Assisted Living Facility Residents and Staff; a NIAID and Lilly Collaborative Study

Assessment of Safety, Tolerability, and Efficacy of XXX in Early Symptomatic Alzheimer's Disease

A Phase III, 52-Week, open-label, single-arm study to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of XXX in subjects with Parkinson's disease.

An Open-Label Study in Subjects with Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of XXX for up to 4 Weeks in an Outpatient Environment

A Randomized Controlled Study to Compare the Safety and Efficacy of XXX with Immediate-Release Carbidopa-Levodopa in Parkinson's Disease Patients with Motor Fluctuations

An Open-Label Extension Study of the Safety and Clinical Utility of XXX in Parkinson’s Disease Patients with Motor Fluctuations  

A Global, Phase II, Randomized, Double-Blind, Placebo-Controlled, Response-Adaptive Dose-Ranging Study of XXX, an Oral Factor Xia Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarction in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack (TIA)

A Randomized, Double-Blind, Placeb0-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of XXX when Added to Standard of Care in Progressive Forms of Multiple Sclerosis

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of XXX when Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

Effect of XXX on Cognition in Mild-to-Moderate Parkinson's Disease Dementia (PDD)

A Randomized Double-Blind, Placebo-Controlled, Dose Finding Study to Evaluate the Efficacy and Safety of XXX as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects with Drug Resistant Epilepsy

A Prospective, Open Label Study to Assess the Pharmacokinetics, Safety and Efficacy of XXX When Used to Treat Children with Invasive Candidiasis, Including Candidemia (Pediatric Inpatient)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral XXX Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Complete Remission

Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of XXX Plus R-Chop Chemotherapy (R2-CHOP) Versus Placebo Plus R-Chop Chemotherapy in Subjects with previously Untreated Activated B-Cell Type Diffuse Large B-Cell Lymphoma

A Phase IIIB Study to Evaluate the Potential of XXX to Reduce Cardiovascular Risk in Patients with Stable Cardiovascular Disease and Glucose Abnormalities

A Phase Ill, Randomized, Double Blind Study of XXX versus rituximab for the first line treatment of patients with CD20 Positive, Low Tumor Burden Follicular Lymphoma

A Phase Ill, Multi-Site, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of XXX in Subjects with Moderate to Severe Chronic Plaque Psoriasis

A Phase I/II Safety, Pharmacokinetic, and Pharmacodynamic Study of XXX with Flucytosine and Maltose for the Treatment of Advanced and/or Metastatic Solid Tumors

An Open-Label, One-Arm, One-Sequence Crossover Drug-Drug Interaction Study in Advanced Solid Tumor Subjects to Evaluate the Potential Effect of XXX on the Pharmacokinetics of Paclitaxel

A Phase I Study of Oral XXX to Assess Drug-Drug Interaction with Ketoconazole, Relative Bioavailability, Food Effect, and Safety and Tolerability in Patients with Advanced Nonhematologic Malignancies or Lymphoma

An Open Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of XXX Given Twice Weekly for Three Consecutive Weeks in Cancer Patients

A Phase I/II Open-Label Dose-Escalation Clinical Trial of XXX in Combination with Gemcitabine in Cancer Patients

A Phase Ill Randomized Double-Blind Study to Assess the Efficacy and Safety of XXX Plus Capecitabine Versus Placebo Plus Capecitabine in Patients with Refractory Advanced Colorectal Cancer

A Phase 2, Multicenter, Two-Tier Study of XXX in Combination with Depot Octreotide in patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma

A Randomized Double-Blind Phase 3 Trial Comparing XXX and Pegylated Liposomal Doxorubicin (PLD/DOXIL©/CAELYX©) In Combination Versus PLD in Participants with Platinum-Resistant Ovarian Cancer

A Phase l, Multi-Center, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of XXX in Patients with Advanced Solid Tumors

Randomized, Double-blind, Placebo-controlled, Phase 3 Study of XXX in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma

Phase I Trial of XXX and GMCSF Augmented Autologous Tumor Cell vaccine for Advanced Cancer

Randomized Phase Il Trial of Adjuvant XXX and GMCSF Augmented Autologous Tumor Cell Vaccine for High-Risk Stage Illc Ovarian Cancer

Phase Il Trial of Adjuvant XXX and GMCSF Augmented Autologous Tumor Cell Vaccine Integrated with Chemotherapy for Patients with Recurrent Cisplatinum Sensitive Ovarian Cancer Participating in Study XXX

Phase Il Trial of Adjuvant XXX and GMCSF Augmented Autologous Tumor Cell Vaccine Integrated with Bevacizumab for Patients with Recurrent/Refractory Ovarian Cancer Participating in Study XXX

Phase Il Trial of XXX Autologous Tumor Cell Vaccine in Advanced Melanoma  

Randomized Phase Il Trial of Post-Operative Adjuvant Chemotherapy XXX Autologous Tumor Cell Vaccine in Colorectal Carcinoma with Liver Metastases

Phase I Study of Two different doses of the Subcutaneous Administration of an Immunotherapeutic Vaccine, XXX in Advanced Stage Patients with Ovarian, Breast or Prostate Cancer

A Phase I Dose Escalation Study of XXX in Adult Patients with Metastatic Solid Tumors

Prospective, Randomized, Single-Blinded, Multi-Center Phase Il Trial of the HER2/neu Peptide XXX+GM-CSF Vaccine Versus GM-CSF Alone in HLA-A2+ OR the Modified HER2/neu Peptide XXX +GM-CSF Vaccine Versus GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients to Prevent Recurrence

A Multi-Center Phase I Evaluation of the Doublet MHC Class I and Il HER2/neu Peptide Vaccines (GP2 and XXX, respectively) in HLA-A2+ or HLA-A3+ Patients with Intermediate to High- Risk Breast or Ovarian Cancer

A Phase I Open-Label Safety and Pharmacokinetic Study of Escalating Doses of XXX for Infusion in Subjects with Advanced Solid Tumors

Compassionate Trial of Nanocomplex Mediated GNE Gene Replacement in Hereditary Inclusion Body Myopathy II  

A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with XXX to Dacarbazine or Temozolomide in Subjects with Recurrent Metastatic Melanoma

A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of XXX Administered Orally Daily to Subjects with Solid Tumors or Lymphoma

A Randomized Phase 2 Study of Erlotinib plus XXX versus Erlotinib plus Placebo in Previously Treated Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase I Trial of XXX-GMCSF Gene Modified Autologous Tumor Cell Vaccine for Advanced Cancer

A Randomized, Open Label, Multi-Center, Phase Il Study of a Multi-Antigen Therapeutic Vaccine in Patients with Metastatic Melanoma

A Phase Il Trial of Oral XXX, an mTOR Inhibitor, in Combination with Trastuzumab for Patients with HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer

Phase Ill Study of XXX in Advanced Non-small Cell Lung Cancer: An International Multicenter, Randomized, Double-blinded, Placebo controlled Study of XXX Maintenance Therapy for Stages Ill / lV NSCLC Subjects Who Have Responded to or Have Stable Disease Following One Regimen of Front-line, Platinum-based Combination Chemotherapy  

A Phase I Trial of XXX an mTOR Inhibitor, in combination with Bevacizumab for Patients with Advanced Cancers  

A Phase I/II Study to Investigate the Safety, Tolerability and Potential Activity of XXX in Relapsed and/or Refractory Stage 111b (with Malignant Pleural or Pericardial Effusion), or Stage IV NSCLC Patients

A Phase 1b Safety Study of XXX in Cirrhotic Patients with Hepatocellular Carcinoma (HCC)

A Phase lb/ll Study of XXX in Patients with Second Line Gastric, Gastro-esophageal, or Esophageal Adenocarcinoma

A Phase 1b, Single-Arm, Open Label Clinical Trial to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients with HER2-Postive Metastatic or Locally Advanced Inoperable Cancer

A Phase I Dose Escalation of the Safety and Pharmacokinetics of XXX Orally Administered to Patients with Advanced Malignancies

A Phase 3 Randomized, Open-Label Study of Docetaxel in Combination with XXX and XXX versus Docetaxel and Prednisone in Taxane-Naive Patients with Metastatic Hormone-Refractory Prostate Cancer with Pain

An Open Label Single Arm Trial Investigating XXX, A Human Monoclonal Anti-EGF Receptor Antibody, in Combination with Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinoma of the Head and Neck (SCCHN) Who Have Failed Standard Platinum Based Chemotherapy

A Phase Il Study of the Efficacy, Safety, and Immunogenicity of XXX in Patients with Stage IllC and Stage IV Malignant Melanoma

A Phase I Dose- Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Cyclin-Dependent Kinase (CDK) Inhibitor XXX Administered Weekly in Subjects with Advanced Malignancies

A Phase Il, single arm study of XXX Monotherapy in Subjects with Platinum Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Double-Blind, Randomized, Placebo-Controlled Phase Ill Study to Assess Efficacy of XXX as Adjuvant Therapy in Patients with Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer

A Pivotal Trial to Determine the Efficacy and Safety of XXX when Administered as Maintenance Therapy to Patients with Metastatic Soft-Tissue or Bone Sarcomas

A Phase Il, Randomized Trial of Chemo radiation with or without XXX in Subjects with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Phase I Trial of Intertumoral Administration of XXX A Eplication Competent Herpes Simplex Virus Type 1, In Patients With Refractory Head and Neck Cancer or Solid tumors with cutaneous and/or Superficial Lesions

A Randomized, Double Blind, Placebo-Controlled Evaluation of the Effectiveness and Safety of XXX in Nursing Home Residents with Moderate to Severe Alzheimer's Disease

A Multi-Center, Double Blind, Placebo-Controlled, Fixed-Dose, 8 Week Evaluation of the Efficacy and Safety of XXX in the Treatment of Major Depression in Patients with Type Il Bipolar Disorder

A Multi-Center, Randomized, Parallel-Group, Double Blind, Phase Il Comparison of the Efficacy and Safety of XXX (Oral Tablets 400 mg to 800 mg Daily in Divided Doses) to Placebo When Used as Adjunct to Mood Stabilizers (Lithium or Divalproex) in the Maintenance Treatment of Bipolar I Disorder in Adult Patients

A Four-Week Double Blind Multi-Center Study Comparing the Efficacy and Safety of Ziprasidone to Aripiprazole in Subjects with Schizophrenia or Schizoaffective Disorder Needing Inpatient Care

A Bipolar I Disorder Psychometric Validation of Functional Status Questionnaire Designed for Use in Bipolar Disorder.

A Randomized, Multi-Center, Double Blind, Placebo-Controlled, 18 Month Study of the Efficacy of XXX in Patients with Mild-to-Moderate Dementia of the Alzheimer's Type

Randomized, Double Blind, Placebo and Active-Controlled, Parallel-Group, Dose Response Study to Evaluate the Efficacy and Safety of 3 Fixed Dosages of Extended Release XXX (3, 9, and 15 mg/day) and XXX (10 mg/day), With Open-Label Extension, in the Treatment of Subjects with Schizophrenia

A Multi-Center, Randomized, Double Blind, Placebo Controlled Study of XXX Monotherapy in the Treatment of Acutely Manic Patients with Bipolar I Disorder

Additional Information:
OriginallY From:
Louisiana.
Fun Fact:
I like to quilt and crochet.
Recent Updates
Knowledge Base Contributions
Frequently Asked Questions
Glossary Terms